New approaches to the treatment of actinic keratosis

American Journal of Cancer

Volumn 2, Issue 3, 2003, Pages 151-168

  Jeffes III, Edward W B ^a,b   Chen, Julie T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Dermatology 11 110   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; DICLOFENAC; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IMIQUIMOD; PROTOPORPHYRIN; SUNSCREEN; ZINC OXIDE;

ACTINIC KERATOSIS; BURNING SENSATION; CELL PROLIFERATION; CONTACT DERMATITIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRY SKIN; EDEMA; EPIDERMIS CELL; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; KERATINOCYTE; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK FACTOR; SKIN DEFECT; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRAVIOLET A RADIATION;

EID: 0038373020     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302030-00001     Document Type: Review

References (34)

1. Jeffes EWB, Tang EH. Actinic keratosis: current treatment options. Am J Clin Dermatol 2000; 1 (3): 167-79
2. Kirkham N. Tumors and cysts of the epidermis. In: Elder D, Elenitsas R, Jaworsky C, et al., editors. Lever's histopathology of the skin. Philadelphia (PA): Raven, 1997: 701-5
3. Olsen EA, Abernethy L, Kulp-Shorten C, et al. A double blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratosis on the head and neck. J Am Acad Dermatol 1991; 24: 738-43
4. Black HS, Herd A, Goldberg LH, et al. Effect of low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994; 330: 1272-5
5. Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422: 185-90
6. Barta U, Gräfe T, Wollina U. Radiation therapy for extensive actinic keratosis. J Eur Acad Dermatol Venereol 2000; 14: 293-5
7. Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131: 170-5
8. Mitchnick MA, Fairhurst D, Pinnell SR. Microfine zinc oxide (Z-Cote) as a photostable UVA/UVB sunblock agent. J Am Acad Dermatol 1999; 40 (1): 85-90
9. Aldara imiquimod cream 5%: company product report. St. Paul (MN): 3M Pharmaceuticals, 2001: 55133-3275
10. Levulan Kerastick: FDA package insert. Wilmington (MA): DUSA Pharmaceuticals Inc., 2001: 01887
11. Solaraze diclofenac sodium gel 3%: company product report. Malvern (PA): Bioglan Pharma Inc., 2001: 19355
12. Efudex® fluorouracil cream and solution 5%: company product report. Costa Mesa (CA): ICN Pharmaceuticals Inc., 2001: 92626
13. Pearlman DL. Weekly pulse dosing: effective and comfortable topical fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25: 665-7
14. Carac® fluorouracil cream 0.5%: FDA package insert. Berwyn (PA): Dermik Laboratories Inc., 2001: 19312
15. Z-Cote microfine zinc oxide: company educational pamphlet. A sunscreen primer with emphasis on microfine zinc oxide as a transparent full-spectrum sunblock. Wainscott (NY): SunSmart Inc., 2001: 11975
16. Z-Cote microfine zinc oxide: company product report. Bethlehem (PA): Applied Therapeutics, distributed by NPR Healthcare, 2001; 18015
17. Solbar Zinc microfine zinc oxide: company product report. Glendale (CA): Person & Covey Inc., 2001: 91221-5018
18. Stockfleth E, Meyer T, Bennighoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050-3
19. Jeffes EWB, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dcrmatol 2001; 45: 96-104
20. Weiss J, Furst K, Connolly M, et al. Actinic keratosis may be treated effectively and safely with once-daily 5-fluorouracil 0.5% topical cream [poster]. 59th Annual Meeting of American Academy of Dermatology; 2001 Mar 2-7; Washington, DC
21. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176-81
22. Szeimies RM, Karrer S, Radakovic-Fijan, et al. Photodynamic therapy using topical methyl-5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62
23. Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41 (3 Pt 1): 414-8
24. Rivers JK, McLean DI. An open label study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-42
25. Carac® fluorouracil cream 0.5%: company product report. Bridgewater (NJ): Aventis Pharma, 2001: 08807-2854
26. Efudex® fluorouracil cream and solution 5%: FDA package insert. Costa Mesa (CA): ICN Pharmaceuticals Inc., 2001: 92626
27. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998; 38: 77-80
28. Jorizzo J, Weiss J, Furst K, et al. Safety of once-daily 0.5% 5-fluorouracil topical cream in the treatment of actinic keratosis [poster]. 59th Annual Meeting of American Academy of Dermatology; 2001 Mar 2-7; Washington, DC
29. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24 (6): 990-1000
30. Levy S, Furst K, Chern W. Pharmacokinetics of topically applied fluorouracil in patients with actinic keratosis [poster]. 59th Annual Meeting of American Academy of Dermatology; 2001 Mar 2-7; Washington, DC
31. Johnson MR, Hageboutros A, Wang K, et al. Toxicity attributed to topical fluorouracil (5-FU) in a dihydropyrimidine dehydrogenase deficient (DPD) patient. Clin Cancer Res 1999; 6: 2006-11
32. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with fluorouracil. Adv Enzyme Regul 2001; 41: 151-7
33. Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98 (3): 610-5
34. Yamaguchi K, Arai Y, Kanda Y, et al. Germline mutation of dihydropyrimidine dehydrogenase among a Japanese population in relation to toxicity to fluorouracil. Jpn J Cancer Res 2001; 92 (3): 337-43